US review raises concern about BMS, AstraZeneca diabetes drug risk
This article was originally published in Scrip
Executive Summary
The heart-health benefits of a diabetes pill developed by Bristol-Myers Squibb and AstraZeneca may not justify the risks associated with the treatment, FDA reviewers said in a report ahead of a panel hearing this week.